生物股份(600201.SH):子公司取得新獸藥註冊證書
格隆匯 10 月 14日丨生物股份(600201.SH)公告,根據國家《獸藥管理條例》和《獸藥註冊辦法》規定,經農業農村部審查,批准金宇生物技術股份有限公司(以下簡稱“公司”)全資子公司金宇保靈生物藥品有限公司(以下簡稱“金宇保靈”)與北京市農林科學院、天津瑞普生物技術股份有限公司、乾元浩生物股份有限公司、豪威生物科技有限公司聯合開發的鴨坦布蘇病毒血凝抑制試驗抗原、陽性血清與陰性血清為新獸藥,並核發了《新獸藥註冊證書》。
新獸藥名稱:鴨坦布蘇病毒血凝抑制試驗抗原、陽性血清與陰性血清
註冊分類:一類
新獸藥註冊證書號:(2020)新獸藥證字48號
研製單位:北京市農林科學院、天津瑞普生物技術股份有限公司、乾元浩生物股份有限公司、金宇保靈生物藥品有限公司、豪威生物科技有限公司。
主要成分與含量:抗原由鴨坦布蘇病毒DTMUV-HB株製備,對0.33%鵝紅細胞的HA效價不低於1:128。陽性血清中鴨坦布蘇病毒血凝抑制抗體不低於1:80。陰性血清中鴨坦布蘇病毒血凝抑制抗體低於1:10。
作用與用途:用於鴨坦布蘇病毒HI抗體的檢測。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.